| Dena'ina Wellness Center | |
|
508 Upland Street Kenai AK 99611 | |
| (907) 335-7550 | |
| (888) 491-3360 |
| Full Name | Dena'ina Wellness Center |
|---|---|
| Speciality | Clinic/Center |
| Location | 508 Upland Street, Kenai, Alaska |
| Authorized Official Name and Position | Christopher Koski (DIRECTOR OF HEALTH SYSTEMS) |
| Authorized Official Contact | 9073357557 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Dena'ina Wellness Center P.o. Box 988 Kenai AK 99611 Ph: (907) 335-7550 | Dena'ina Wellness Center 508 Upland Street Kenai AK 99611 Ph: (907) 335-7550 |
| NPI Number | 1932114600 |
|---|---|
| Provider Enumeration Date | 07/30/2006 |
| Last Update Date | 02/09/2024 |
| Medicare PECOS PAC ID | 4082506225 |
|---|---|
| Medicare Enrollment ID | O20040325000198 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932114600 | NPI | - | NPPES |
| CL9243 | Medicaid | AK |
| Provider Name | Ramzi M Nassar |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1790735579 PECOS PAC ID: 4981622313 Enrollment ID: I20051104000059 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Paul J Carlson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1336191824 PECOS PAC ID: 9739182783 Enrollment ID: I20060814000280 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Jeoffrey W Lanfear |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083887749 PECOS PAC ID: 8022179860 Enrollment ID: I20081211000420 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Kasie S Scheer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083637136 PECOS PAC ID: 1951322627 Enrollment ID: I20090929000409 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Heather L Callum |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1083606461 PECOS PAC ID: 6305033754 Enrollment ID: I20101210000304 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Bruce C Stockhouse |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1689781643 PECOS PAC ID: 5991839227 Enrollment ID: I20110830000778 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Fridrik Gudmundsson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1831531037 PECOS PAC ID: 9335383819 Enrollment ID: I20130924000297 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Colleen Nusbaum |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1295996858 PECOS PAC ID: 5092946988 Enrollment ID: I20140317001994 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Kelly V Hall |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518213503 PECOS PAC ID: 0547418659 Enrollment ID: I20160209002446 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Amanda Mcglasson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1508319195 PECOS PAC ID: 8527354844 Enrollment ID: I20160912002120 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | William Phillips |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1902953144 PECOS PAC ID: 6800848870 Enrollment ID: I20160921002915 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Twila J Berry |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1952552721 PECOS PAC ID: 3375830094 Enrollment ID: I20160923001474 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Meagan C Lincoln |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1275089997 PECOS PAC ID: 1557640489 Enrollment ID: I20161117001411 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Collin T Atkinson |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1942754742 PECOS PAC ID: 0143508275 Enrollment ID: I20170428002057 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Catherine Annabel Henderson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093145567 PECOS PAC ID: 8729202452 Enrollment ID: I20180320001268 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Summer Ann Cross |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275711491 PECOS PAC ID: 8921177353 Enrollment ID: I20180517001301 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Bonnie M Turner |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740678556 PECOS PAC ID: 1153642970 Enrollment ID: I20180531002670 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Andrew W Fuhrman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1184923450 PECOS PAC ID: 9739346099 Enrollment ID: I20190401000197 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Karen Lynn Lewis |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306194576 PECOS PAC ID: 5890937726 Enrollment ID: I20190408002452 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Kristen J Bracklein |
|---|---|
| Provider Type | Practitioner - Osteopathic Manipulative Medicine |
| Provider Identifiers | NPI Number: 1730255357 PECOS PAC ID: 6507814068 Enrollment ID: I20190417000936 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Robert Byron Mitchell |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1346684313 PECOS PAC ID: 5799903886 Enrollment ID: I20190702003139 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Marion A Ruth |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1740789288 PECOS PAC ID: 3678817731 Enrollment ID: I20190820003864 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Stuart E Marcotte |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1548607211 PECOS PAC ID: 7214223197 Enrollment ID: I20200603001203 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Laina Gay Cafego |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1831539378 PECOS PAC ID: 2769778588 Enrollment ID: I20210318000873 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Wayne Russell Millar |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1821172594 PECOS PAC ID: 7416366232 Enrollment ID: I20210507000987 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Matthew Douglas Richards |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1033347836 PECOS PAC ID: 5698064590 Enrollment ID: I20210519002295 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Travis Alan Perkins |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1982840203 PECOS PAC ID: 7315337482 Enrollment ID: I20211203000600 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Zachary Barrickman |
|---|---|
| Provider Type | Practitioner - Dentist |
| Provider Identifiers | NPI Number: 1164902334 PECOS PAC ID: 5193064434 Enrollment ID: I20211204000161 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Stephen Andrew Kronlage |
|---|---|
| Provider Type | Practitioner - Registered Dietitian Or Nutrition Professional |
| Provider Identifiers | NPI Number: 1376211201 PECOS PAC ID: 0840681011 Enrollment ID: I20211222002085 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Sarah Huot |
|---|---|
| Provider Type | Practitioner - Occupational Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1093356412 PECOS PAC ID: 1850783283 Enrollment ID: I20220117000265 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Mary M Bassir |
|---|---|
| Provider Type | Practitioner - Other (physician) |
| Provider Identifiers | NPI Number: 1700449048 PECOS PAC ID: 3870986979 Enrollment ID: I20220214001813 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Frank J Novy |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1770517781 PECOS PAC ID: 8921029794 Enrollment ID: I20220301000083 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Nissa Loving Kisler |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457837486 PECOS PAC ID: 0648501387 Enrollment ID: I20220419001417 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Deborah Hoenig |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1508222019 PECOS PAC ID: 6608171632 Enrollment ID: I20220425001859 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Lisa Mapuranga |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1972696722 PECOS PAC ID: 5698098846 Enrollment ID: I20221116002885 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Alison P Liewen |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1306374236 PECOS PAC ID: 0547694424 Enrollment ID: I20230127000997 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Rebecca Strong |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1356990055 PECOS PAC ID: 3870954902 Enrollment ID: I20230804001647 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | John Cassano |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1508353632 PECOS PAC ID: 1759753478 Enrollment ID: I20230805000125 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Deborah Cox |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1770908964 PECOS PAC ID: 2264663335 Enrollment ID: I20230911001491 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | Daniel Iqbal |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1093276396 PECOS PAC ID: 2668843863 Enrollment ID: I20231027001008 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
| Provider Name | James Edwin Dickey |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275516494 PECOS PAC ID: 5395188973 Enrollment ID: I20240212000072 |
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
News Archive
Using a new cellular model, innovative gene therapy approaches for the hereditary immunodeficiency Chronic Granulomatous Disease can be tested faster and cost-effectively in the lab for their efficacy.
A researcher at Albert Einstein College of Medicine of Yeshiva University has helped to develop the first genetic blood test for predicting the chances that in vitro fertilization will lead to a successful pregnancy.
The COVID-19 pandemic has once again highlighted the uncertainty inherent in science. The results of a Germany-wide study conducted by researchers at the Max Planck Institute for Human Development and Charite - Universitaetsmedizin Berlin show that most Germans want to be openly informed about this uncertainty.
The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.
› Verified 1 days ago
Kenai Medical Center - Cph Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 805 Frontage Rd, Suite 123, Kenai, AK 99611 Phone: 907-283-4611 Fax: 907-283-3992 | |
Capstone Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 10543 Kenai Spur Hwy, Kenai, AK 99611 Phone: 907-357-9590 Fax: 907-357-9593 | |
Ideal Option, Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 416 Frontage Rd # 400, Kenai, AK 99611 Phone: 509-222-1275 Fax: 509-491-3031 | |
Independence Healthcare Primary Care Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 Trading Bay Rd Ste 8, Kenai, AK 99611 Phone: 907-283-4633 Fax: 907-262-0832 | |
Kenai Family Practice Llc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 135 Bidarka St, Suite 101, Kenai, AK 99611 Phone: 907-335-0034 Fax: 907-335-0064 | |
Redoubt Medical Group Llc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 416 Frontage Rd Ste 200, Kenai, AK 99611 Phone: 907-283-6030 Fax: 907-283-3194 | |
Kenai Medical Center Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 805 Frontage Rd, Ste 123, Kenai, AK 99611 Phone: 907-283-4611 Fax: 907-283-3992 |